Fidelis Research — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Fidelis Research, founded in 2020 and headquartered in London, is a services-focused company in the life sciences sector. Its core business is providing biospecimen collections and custom contract research services to support global research and clinical trials. Notably, the company was acquired by BioIVT in September 2022, integrating it into a larger global biospecimen and research services network. Fidelis's operations span biospecimen procurement, lab services, clinical trial management, and patient support programs.

AI / Machine LearningDrug Delivery

Technology Platform

Integrated biospecimen procurement network and clinical research site management platform across Eastern Europe, with supporting laboratory processing capabilities.

Opportunities

Leveraging BioIVT's global reach to scale its specialized Eastern European biospecimen and clinical services.

Growing demand for clinical trial execution in cost-effective regions with treatment-naive patient populations.

Expanding service integration to offer seamless biospecimen-to-clinical-data solutions.

Risk Factors

Integration challenges following the 2022 acquisition by BioIVT.

Operational and regulatory risks associated with concentration in specific Eastern European countries.

Intense competition in the global CRO and biospecimen services market.

Competitive Landscape

Operates in the highly competitive Contract Research Organization (CRO) and biospecimen services sector. Competes with global giants (IQVIA, LabCorp, PPD) and niche regional providers. Its differentiation lies in its integrated model combining biospecimens and clinical site management within a focused Eastern European network, now amplified by BioIVT's global footprint.

More companies in Digital Health & Biotech SaaS →More companies in Europe - Other →